US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ArriVent BioPharma

21.43

-0.3750-1.72%

Post-market: 21.430.00000.00%16:34 EDT

Volume:421.66K

Turnover:9.13M

Market Cap:947.24M

PE:-4.96

High:22.71

Open:21.65

Low:21.30

Close:21.81

52wk High:27.22

52wk Low:15.47

Shares:44.20M

Float Shares:25.53M

Volume Ratio:0.80

T/O Rate:1.65%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.3239

EPS(LYR):-4.3239

ROE:-58.88%

ROA:-36.49%

PB:3.08

PE(LYR):-4.96

Loading ...

Overview Company News Filings

ArriVent posts FY 2025 net loss of USD 166.3 million (up 2.1x)

Press Release: ArriVent BioPharma Reports Full Year 2025 Financial Results

Big Money Moves Out of ArriVent BioPharma

Hillhouse Investment Management Reports Disposal of ArriVent Biopharma Common Shares

ArriVent BioPharma Up Nearly 11%, on Pace for Largest Percent Increase Since August 2024 -- Data Talk

ArriVent Buy Rating: Favorable Risk‑Reward on Firmonertinib Ahead of Pivotal FURVENT Phase 3 Readout

ArriVent BioPharma Initiated at Overweight by Cantor Fitzgerald

BRIEF-Arrivent Announces First Patient Dosed In Global Pivotal Phase 3 Alpacca Trial Evaluating Firmonertinib For First-Line Treatment Of EGFR PACC Mutant Non-Small Cell Lung Cancer

Arrivent Announces First Patient Dosed in Global Pivotal Phase 3 Alpacca Trial Evaluating Firmonertinib for First-Line Treatment of Egfr Pacc Mutant Non-Small Cell Lung Cancer

THOMSON REUTERS

ArriVent BioPharma Initiated at Buy by BTIG

BTIG Initiates ArriVent BioPharma at Buy With $45 Price Target

MT Newswires Live

Arrivent Biopharma Inc : Btig Initiates Coverage With Buy Rating; Price Target $45

THOMSON REUTERS

U.S. RESEARCH ROUNDUP-JP Morgan, Pepsico, Pfizer

ArriVent BioPharma Initiated at Buy by Truist Securities

Arrivent Biopharma Inc : Truist Securities Initiates Coverage With Buy Rating; Target Price $43

THOMSON REUTERS

Truist Initiates ArriVent BioPharma at Buy With $43 Price Target

MT Newswires Live

Stock Track | ArriVent BioPharma Soars 5.21% Ahead of Anticipated Q4 Earnings Report

Stock Track | ArriVent BioPharma Soars 5.21% Ahead of Q4 Earnings Report

Calendar of U.S. Earnings Expected in the Week Ahead

ArriVent BioPharma, Inc.: Strategic Advancements and Promising Developments Drive Buy Rating with $45 Price Target

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/AVBP/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AVBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVBP\",,,,,undefined,":{"symbol":"AVBP","market":"US","secType":"STK","nameCN":"ArriVent BioPharma","latestPrice":21.43,"timestamp":1774641600000,"preClose":21.805,"halted":0,"volume":421656,"hourTrading":{"tag":"盘后","latestPrice":21.43,"preClose":21.43,"latestTime":"16:34 EDT","volume":10492,"amount":224843.56,"timestamp":1774643652483,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.017197890392111902,"floatShares":25528400,"shares":44201622,"eps":-4.323888,"marketStatus":"Market Closed","change":-0.375,"latestTime":"03-27 16:00:00 EDT","open":21.65,"high":22.705,"low":21.3,"amount":9132150.593232,"amplitude":0.064435,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.323888,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1706245200000,"exchange":"NASDAQ","adjPreClose":21.805,"preHourTrading":{"tag":"盘前","latestPrice":21.4,"preClose":21.805,"latestTime":"09:02 EDT","volume":1450,"amount":31785.648650000003,"timestamp":1774616525062,"change":-0.405,"changeRate":-0.018574,"amplitude":0.045402},"postHourTrading":{"tag":"盘后","latestPrice":21.43,"preClose":21.43,"latestTime":"16:34 EDT","volume":10492,"amount":224843.56,"timestamp":1774643652483,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7959166105081306,"impliedVol":0.7975,"impliedVolPercentile":0.6049},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVBP\",,,,,undefined,":{"symbol":"AVBP","floatShares":25528400,"roa":"-36.49%","roe":"-58.88%","lyrEps":-4.323888,"volumeRatio":0.7959166105081306,"shares":44201622,"dividePrice":0,"high":22.705,"amplitude":0.064435,"preClose":21.805,"low":21.3,"week52Low":15.47,"pbRate":"3.08","week52High":27.22,"institutionHeld":0,"latestPrice":21.43,"eps":-4.323888,"divideRate":0,"volume":421656,"delay":0,"ttmEps":-4.323888,"open":21.65,"prevYearClose":20.12,"prevWeekClose":22.02,"prevMonthClose":22.97,"prevQuarterClose":20.12,"fiveDayClose":22.02,"twentyDayClose":22.97,"sixtyDayClose":20.72},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AVBP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-05","symbol":"AVBP","fiscalQuarterEnding":"2025/12","expectedEps":-0.87,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"post","actualEps":-0.78},{"market":"US","date":"2025-11-10","symbol":"AVBP","fiscalQuarterEnding":"2025/09","expectedEps":-0.78,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"pre","actualEps":-0.83},{"market":"US","date":"2025-08-11","symbol":"AVBP","fiscalQuarterEnding":"2025/06","expectedEps":-0.7,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"pre","actualEps":-0.9},{"market":"US","date":"2025-05-12","symbol":"AVBP","fiscalQuarterEnding":"2025/03","expectedEps":-0.66,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"pre","actualEps":-1.9},{"market":"US","date":"2025-03-03","symbol":"AVBP","fiscalQuarterEnding":"2024/12","expectedEps":-0.78,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740978000000,"reportTimeType":"pre","actualEps":-0.6}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AVBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AVBP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3846,"buy":0.6154,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6154,"analysts":13,"updateTime":1766462400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AVBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AVBP","date":"2026-03-27","current":-4.956188,"percent":0.824762,"low":-15.980041,"twenty":-11.188316,"median":-8.205246,"eighty":-5.878182,"high":-4.80343,"avg":-8.478771,"sd":2.634144,"marketCap":963816367},"quantilePoints":[{"date":"2024-01-26","current":-15.452095,"twenty":-15.452095,"median":-15.452095,"eighty":-15.452095,"marketCap":905214654},{"date":"2024-02-02","current":-11.990156,"twenty":-12.001066,"median":-11.872873,"eighty":-10.91006,"marketCap":702407320},{"date":"2024-02-09","current":-12.548731,"twenty":-12.548731,"median":-12.001066,"eighty":-11.75559,"marketCap":735129780},{"date":"2024-02-16","current":-12.588659,"twenty":-12.548731,"median":-12.126596,"eighty":-11.919241,"marketCap":737468829},{"date":"2024-02-23","current":-11.219707,"twenty":-12.556717,"median":-11.998256,"eighty":-11.67237,"marketCap":657272853},{"date":"2024-03-01","current":-12.286349,"twenty":-12.548731,"median":-11.990156,"eighty":-11.204877,"marketCap":719758884},{"date":"2024-03-08","current":-11.464977,"twenty":-12.548731,"median":-11.964074,"eighty":-11.315533,"marketCap":671641299},{"date":"2024-03-15","current":-10.59227,"twenty":-12.5031,"median":-11.767288,"eighty":-11.121598,"marketCap":620516364},{"date":"2024-03-22","current":-10.386927,"twenty":-12.327418,"median":-11.658912,"eighty":-10.920492,"marketCap":608486967},{"date":"2024-03-28","current":-10.267144,"twenty":-12.279504,"median":-11.507757,"eighty":-10.718898,"marketCap":601469820},{"date":"2024-04-05","current":-8.84046,"twenty":-12.261251,"median":-11.265338,"eighty":-10.410884,"marketCap":612935625},{"date":"2024-04-12","current":-8.536116,"twenty":-12.10149,"median":-11.165519,"eighty":-9.961411,"marketCap":591834562},{"date":"2024-04-19","current":-7.487821,"twenty":-11.997694,"median":-11.025772,"eighty":-8.805678,"marketCap":519153125},{"date":"2024-04-26","current":-7.507145,"twenty":-11.992272,"median":-10.91658,"eighty":-8.501334,"marketCap":520492875},{"date":"2024-05-03","current":-8.115832,"twenty":-11.986485,"median":-10.803317,"eighty":-8.191193,"marketCap":562695000},{"date":"2024-05-10","current":-8.079495,"twenty":-11.960082,"median":-10.543786,"eighty":-8.115832,"marketCap":602552562},{"date":"2024-05-17","current":-9.049573,"twenty":-11.929189,"median":-10.386927,"eighty":-8.101297,"marketCap":674899062},{"date":"2024-05-24","current":-8.479203,"twenty":-11.828069,"median":-10.210104,"eighty":-8.115832,"marketCap":632362000},{"date":"2024-05-31","current":-8.739687,"twenty":-11.762609,"median":-9.361752,"eighty":-8.133223,"marketCap":651788375},{"date":"2024-06-07","current":-8.241175,"twenty":-11.7192,"median":-8.959751,"eighty":-8.180566,"marketCap":614610312},{"date":"2024-06-14","current":-8.456747,"twenty":-11.662334,"median":-8.912923,"eighty":-8.216398,"marketCap":630687312},{"date":"2024-06-21","current":-7.455231,"twenty":-11.653208,"median":-8.84046,"eighty":-8.15931,"marketCap":555996250},{"date":"2024-06-28","current":-7.81452,"twenty":-11.61214,"median":-8.79358,"eighty":-8.133223,"marketCap":582791250},{"date":"2024-07-05","current":-8.205246,"twenty":-11.533425,"median":-8.753505,"eighty":-8.152944,"marketCap":611930812},{"date":"2024-07-12","current":-8.268121,"twenty":-11.43988,"median":-8.706383,"eighty":-8.152944,"marketCap":616619937},{"date":"2024-07-15","current":-8.259139,"twenty":-11.414782,"median":-8.695535,"eighty":-8.154535,"marketCap":615950062},{"date":"2024-08-02","current":-9.655872,"twenty":-11.389685,"median":-8.706383,"eighty":-8.156127,"marketCap":720115625},{"date":"2024-08-09","current":-10.262171,"twenty":-11.294999,"median":-8.753505,"eighty":-8.186872,"marketCap":765332187},{"date":"2024-08-16","current":-10.701201,"twenty":-11.237959,"median":-8.81702,"eighty":-8.205246,"marketCap":801359406},{"date":"2024-08-23","current":-10.705686,"twenty":-11.199173,"median":-8.912923,"eighty":-8.209568,"marketCap":801695265},{"date":"2024-08-30","current":-12.010819,"twenty":-11.389685,"median":-8.993434,"eighty":-8.224295,"marketCap":899430214},{"date":"2024-09-06","current":-11.93009,"twenty":-11.657877,"median":-9.253918,"eighty":-8.235785,"marketCap":893384753},{"date":"2024-09-13","current":-10.669806,"twenty":-11.694732,"median":-9.655872,"eighty":-8.248361,"marketCap":799008394},{"date":"2024-09-20","current":-10.85369,"twenty":-11.663166,"median":-9.763659,"eighty":-8.262732,"marketCap":812778610},{"date":"2024-09-27","current":-10.544226,"twenty":-11.657877,"median":-10.060071,"eighty":-8.269917,"marketCap":789604344},{"date":"2024-10-04","current":-11.49056,"twenty":-11.61214,"median":-10.208101,"eighty":-8.279798,"marketCap":860470578},{"date":"2024-10-11","current":-12.463804,"twenty":-11.739278,"median":-10.315491,"eighty":-8.299559,"marketCap":933351966},{"date":"2024-10-18","current":-13.002004,"twenty":-11.938503,"median":-10.371883,"eighty":-8.317243,"marketCap":973655038},{"date":"2024-10-25","current":-13.912458,"twenty":-11.99333,"median":-10.426855,"eighty":-8.325491,"marketCap":1041834400},{"date":"2024-10-31","current":-14.114283,"twenty":-12.114871,"median":-10.539741,"eighty":-8.328911,"marketCap":1056948052},{"date":"2024-11-08","current":-15.980041,"twenty":-12.249611,"median":-10.573379,"eighty":-8.330997,"marketCap":1196665367},{"date":"2024-11-15","current":-11.674764,"twenty":-12.282511,"median":-10.59227,"eighty":-8.332793,"marketCap":946216280},{"date":"2024-11-22","current":-11.05527,"twenty":-12.272349,"median":-10.669806,"eighty":-8.342492,"marketCap":896007510},{"date":"2024-11-29","current":-12.456408,"twenty":-12.274941,"median":-10.685503,"eighty":-8.352544,"marketCap":1009566943},{"date":"2024-12-06","current":-11.870175,"twenty":-12.284404,"median":-10.712096,"eighty":-8.353452,"marketCap":962053946},{"date":"2024-12-13","current":-10.760075,"twenty":-12.274941,"median":-10.748293,"eighty":-8.371867,"marketCap":872082526},{"date":"2024-12-20","current":-10.664448,"twenty":-12.261979,"median":-10.759506,"eighty":-8.380399,"marketCap":864332179},{"date":"2024-12-27","current":-11.46688,"twenty":-12.254096,"median":-10.803317,"eighty":-8.380399,"marketCap":929367700},{"date":"2025-01-03","current":-11.421146,"twenty":-12.244582,"median":-10.85369,"eighty":-8.380399,"marketCap":925661012},{"date":"2025-01-10","current":-11.167527,"twenty":-12.234172,"median":-10.860965,"eighty":-8.382195,"marketCap":905105744},{"date":"2025-01-17","current":-10.177999,"twenty":-12.217129,"median":-10.850538,"eighty":-8.390279,"marketCap":824906501},{"date":"2025-01-24","current":-11.329677,"twenty":-12.196013,"median":-10.850538,"eighty":-8.405549,"marketCap":918247637},{"date":"2025-01-31","current":-12.09469,"twenty":-12.164539,"median":-10.860965,"eighty":-8.437266,"marketCap":980250413},{"date":"2025-02-07","current":-11.383727,"twenty":-12.161213,"median":-10.897572,"eighty":-8.450678,"marketCap":922628268},{"date":"2025-02-14","current":-11.16337,"twenty":-12.157147,"median":-10.9231,"eighty":-8.461238,"marketCap":904768772},{"date":"2025-02-21","current":-11.387884,"twenty":-12.140884,"median":-10.92545,"eighty":-8.479203,"marketCap":922965239},{"date":"2025-02-28","current":-9.8537,"twenty":-12.107163,"median":-10.91658,"eighty":-8.519623,"marketCap":798622715},{"date":"2025-03-07","current":-9.217439,"twenty":-12.09469,"median":-10.885085,"eighty":-8.536116,"marketCap":741893256},{"date":"2025-03-14","current":-9.192082,"twenty":-12.065586,"median":-10.857328,"eighty":-8.618427,"marketCap":739852284},{"date":"2025-03-21","current":-8.258082,"twenty":-12.010819,"median":-10.847386,"eighty":-8.519623,"marketCap":664676489},{"date":"2025-03-28","current":-7.848136,"twenty":-12.001066,"median":-10.781696,"eighty":-8.449161,"marketCap":631680778},{"date":"2025-04-04","current":-7.159258,"twenty":-11.995446,"median":-10.737081,"eighty":-8.380399,"marketCap":576234377},{"date":"2025-04-11","current":-7.125448,"twenty":-11.990156,"median":-10.711139,"eighty":-8.353452,"marketCap":573513081},{"date":"2025-04-17","current":-7.564978,"twenty":-11.988746,"median":-10.703443,"eighty":-8.330997,"marketCap":608889926},{"date":"2025-04-25","current":-8.94696,"twenty":-11.984909,"median":-10.669806,"eighty":-8.330476,"marketCap":720122890},{"date":"2025-05-02","current":-8.908923,"twenty":-11.976101,"median":-10.6604,"eighty":-8.330997,"marketCap":717061432},{"date":"2025-05-09","current":-8.353948,"twenty":-11.95416,"median":-10.580862,"eighty":-8.330997,"marketCap":672392561},{"date":"2025-05-16","current":-5.164444,"twenty":-11.945123,"median":-10.566696,"eighty":-8.323142,"marketCap":658249673},{"date":"2025-05-23","current":-5.537551,"twenty":-11.932894,"median":-10.539741,"eighty":-8.281274,"marketCap":705805133},{"date":"2025-05-30","current":-5.636867,"twenty":-11.923581,"median":-10.506711,"eighty":-8.258716,"marketCap":718463781},{"date":"2025-06-06","current":-6.29987,"twenty":-11.889801,"median":-10.45834,"eighty":-8.241176,"marketCap":802968806},{"date":"2025-06-13","current":-6.342817,"twenty":-11.86768,"median":-10.37894,"eighty":-8.205246,"marketCap":808442816},{"date":"2025-06-20","current":-6.681029,"twenty":-11.831093,"median":-10.360937,"eighty":-8.13004,"marketCap":851550643},{"date":"2025-06-27","current":-6.122711,"twenty":-11.774139,"median":-10.336565,"eighty":-8.056606,"marketCap":780388516},{"date":"2025-07-03","current":-5.951741,"twenty":-11.764948,"median":-10.291317,"eighty":-8.012114,"marketCap":758596999},{"date":"2025-07-11","current":-6.3128,"twenty":-11.752729,"median":-10.177999,"eighty":-7.877518,"marketCap":804616846},{"date":"2025-07-18","current":-6.510523,"twenty":-11.737545,"median":-10.15098,"eighty":-7.814365,"marketCap":829818191},{"date":"2025-07-25","current":-6.146598,"twenty":-11.721024,"median":-10.060071,"eighty":-7.74746,"marketCap":783433107},{"date":"2025-08-01","current":-5.590682,"twenty":-11.706801,"median":-9.819907,"eighty":-7.667253,"marketCap":712577152},{"date":"2025-08-08","current":-5.312724,"twenty":-11.672734,"median":-9.759167,"eighty":-7.57343,"marketCap":677149175},{"date":"2025-08-15","current":-5.522288,"twenty":-11.663891,"median":-9.64689,"eighty":-7.464633,"marketCap":755393737},{"date":"2025-08-22","current":-5.895976,"twenty":-11.659587,"median":-9.496371,"eighty":-7.205647,"marketCap":806510606},{"date":"2025-08-29","current":-5.697269,"twenty":-11.653822,"median":-9.38434,"eighty":-6.898922,"marketCap":779329414},{"date":"2025-09-05","current":-5.789208,"twenty":-11.653208,"median":-9.260758,"eighty":-6.705187,"marketCap":791905786},{"date":"2025-09-12","current":-5.640919,"twenty":-11.550537,"median":-9.192082,"eighty":-6.342817,"marketCap":771621314},{"date":"2025-09-19","current":-5.510425,"twenty":-11.49056,"median":-9.038346,"eighty":-6.3128,"marketCap":753770979},{"date":"2025-09-26","current":-5.092249,"twenty":-11.46688,"median":-8.984996,"eighty":-6.266951,"marketCap":696568768},{"date":"2025-10-03","current":-5.584569,"twenty":-11.464977,"median":-8.939882,"eighty":-6.203238,"marketCap":763913215},{"date":"2025-10-10","current":-6.266699,"twenty":-11.458565,"median":-8.908923,"eighty":-6.178119,"marketCap":857221786},{"date":"2025-10-17","current":-5.820349,"twenty":-11.441934,"median":-8.860202,"eighty":-6.17476,"marketCap":796165526},{"date":"2025-10-24","current":-5.365101,"twenty":-11.433619,"median":-8.84046,"eighty":-6.120027,"marketCap":733892196},{"date":"2025-10-31","current":-5.477801,"twenty":-11.433619,"median":-8.796928,"eighty":-6.098553,"marketCap":749308395},{"date":"2025-11-07","current":-5.454075,"twenty":-11.421146,"median":-8.757651,"eighty":-5.987916,"marketCap":746062880},{"date":"2025-11-14","current":-5.38103,"twenty":-11.41283,"median":-8.728459,"eighty":-5.931566,"marketCap":812417184},{"date":"2025-11-21","current":-5.484932,"twenty":-11.400357,"median":-8.689159,"eighty":-5.895976,"marketCap":828104101},{"date":"2025-11-28","current":-6.2724,"twenty":-11.397031,"median":-8.627903,"eighty":-5.884113,"marketCap":946994421},{"date":"2025-12-05","current":-6.657931,"twenty":-11.389547,"median":-8.556032,"eighty":-5.884113,"marketCap":1005201140},{"date":"2025-12-12","current":-6.649728,"twenty":-11.384558,"median":-8.523142,"eighty":-5.893603,"marketCap":1003962699},{"date":"2025-12-19","current":-5.788435,"twenty":-11.375905,"median":-8.467975,"eighty":-5.893603,"marketCap":873926412},{"date":"2025-12-26","current":-6.094673,"twenty":-11.359859,"median":-8.441726,"eighty":-5.901564,"marketCap":920161536},{"date":"2026-01-02","current":-5.501338,"twenty":-11.346075,"median":-8.391627,"eighty":-5.884113,"marketCap":830580983},{"date":"2026-01-09","current":-5.364625,"twenty":-11.337228,"median":-8.380399,"eighty":-5.844354,"marketCap":809940302},{"date":"2026-01-16","current":-5.988037,"twenty":-11.332171,"median":-8.373482,"eighty":-5.835858,"marketCap":904061805},{"date":"2026-01-23","current":-6.890344,"twenty":-11.326351,"median":-8.3537,"eighty":-5.833294,"marketCap":1040290297},{"date":"2026-01-30","current":-6.152093,"twenty":-11.304731,"median":-8.339979,"eighty":-5.843953,"marketCap":928830622},{"date":"2026-02-06","current":-5.837652,"twenty":-11.270243,"median":-8.329694,"eighty":-5.843953,"marketCap":881357057},{"date":"2026-02-13","current":-6.130218,"twenty":-11.263238,"median":-8.321475,"eighty":-5.843953,"marketCap":925528113},{"date":"2026-02-20","current":-6.313414,"twenty":-11.254838,"median":-8.290577,"eighty":-5.845558,"marketCap":953186625},{"date":"2026-02-27","current":-6.351694,"twenty":-11.246523,"median":-8.270367,"eighty":-5.848589,"marketCap":958966016},{"date":"2026-03-06","current":-6.710988,"twenty":-11.219707,"median":-8.258082,"eighty":-5.878182,"marketCap":1116090955},{"date":"2026-03-13","current":-6.40401,"twenty":-11.204946,"median":-8.245403,"eighty":-5.8814,"marketCap":1065038082},{"date":"2026-03-20","current":-6.07577,"twenty":-11.192473,"median":-8.232192,"eighty":-5.884113,"marketCap":1010449078},{"date":"2026-03-27","current":-5.79537,"twenty":-11.188316,"median":-8.205246,"eighty":-5.878182,"marketCap":963816367}],"updateTime":1774779921488},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AVBP\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2617575134","title":"ArriVent posts FY 2025 net loss of USD 166.3 million (up 2.1x)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617575134","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617575134?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:01","pubTimestamp":1772744492,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma reported a FY 2025 net loss of USD 166.3 million and an operating loss of USD 177.5 million. R&D expense was USD 153.4 million and G&A expense was USD 24.2 million, while interest and investment income was USD 11.2 million. Net cash used in operations totaled USD 160.6 million in FY 2025. Cash and investments were USD 312.8 million as of Dec. 31, 2025, which the company said is expected to fund operations into 3Q 2027. On the pipeline, ArriVent said topline global pivotal Phase 3 data from the FURVENT study of firmonertinib monotherapy in first-line EGFR exon 20 insertion mutant NSCLC is projected for mid-2026, and that enrollment is underway in the global pivotal Phase 3 ALPACCA study in first-line EGFR PACC mutant NSCLC, with the first patient dosed in December 2025. The company also highlighted its ADC program ARR-217 in Phase 1 development, noting it received FDA IND clearance and dosed its first patient in March 2026, and said it plans a U.S. IND filing for ARR-","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL9zc1rX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014039.USD","NDAQ","LU2210149790.SGD","LU2210150020.SGD","SG9999014013.SGD","LU0314104364.USD","AVBP","IE00B3QW5Z07.USD","BK4585","SG9999014005.SGD","BK4139","IE00B64PRP62.GBP","BK4112","BK4588"],"gpt_icon":0},{"id":"2617751445","title":"Press Release: ArriVent BioPharma Reports Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2617751445","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617751445?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:01","pubTimestamp":1772744460,"startTime":"0","endTime":"0","summary":"-- Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR. -- Global pivotal Phase 3 first-line PACC mutant NSCLC study for. -- ADC pipeline advancing with first ADC program, ARR-217, in Phase 1. -- Cash and investments of $312.8 million as of December 31, 2025 expected. \"We are advancing firmonertinib toward potential registration, supported by two pivotal programs targeting uncommon EGFR mutations in non-small cell lung cancer , a high unmet need with limited treatment options,\" said Bing Yao, CEO of ArriVent. \"Our robust clinical data, including CNS activity, underscores the potential of firmonertinib to become a chemotherapy-free standard of care. We look forward to topline pivotal data for firmonertinib monotherapy in frontline EGFR exon 20 insertion mutant NSCLC expected in mid-2026. This is an event driven study, so we plan to continue sharpening our timeline as we look forward to sharing our data.\". -- Positive final data in EGFR PACC mutant NSCLC. In Septembe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","BK4135","BK4080","ADC","AVBP","BK4231","BK4139"],"gpt_icon":0},{"id":"2608959333","title":"Big Money Moves Out of ArriVent BioPharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2608959333","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608959333?lang=en_us&edition=fundamental","pubTime":"2026-02-04 10:04","pubTimestamp":1770170695,"startTime":"0","endTime":"0","summary":"New insider activity at ArriVent BioPharma, Inc. ( ($AVBP) ) has taken place on February 3, 2026. Significant shareholder Hillhouse Capital Managem...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/big-money-moves-out-of-arrivent-biopharma-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/big-money-moves-out-of-arrivent-biopharma-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVBP","BK4139"],"gpt_icon":0},{"id":"2608443800","title":"Hillhouse Investment Management Reports Disposal of ArriVent Biopharma Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2608443800","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608443800?lang=en_us&edition=fundamental","pubTime":"2026-02-04 05:06","pubTimestamp":1770152770,"startTime":"0","endTime":"0","summary":"Hillhouse Investment Management, Ltd., along with HHLR Advisors, Ltd. and other reporting beneficial owners, reported a disposal of common shares of ArriVent Biopharma Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDLfcFgh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Hillhouse Investment Management Reports Disposal of ArriVent Biopharma Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2605414471","title":"ArriVent BioPharma Up Nearly 11%, on Pace for Largest Percent Increase Since August 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2605414471","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605414471?lang=en_us&edition=fundamental","pubTime":"2026-01-23 04:10","pubTimestamp":1769112600,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma, Inc.  is currently at $25.33, up $2.45 or 10.71%. --Would be highest close since June 16, 2025, when it closed at $25.42. --On pace for largest percent increase since Aug. 26, 2024, when it rose 12.65%. --Currently up three consecutive days; up 21.43% over this period. --Down 28.91% from its all-time closing high of $35.63 on Nov. 7, 2024. --Down 7.05% from 52 weeks ago , when it closed at $27.25. --Up 55.4% from its 52-week closing low of $16.30 on April 8, 2025. --Traded as high as $26.00; highest intraday level since Feb. 26, 2025, when it hit $26.32. --Up 13.64% at today's intraday high; largest intraday percent increase since Aug. 26, 2024, when it rose as much as 15.66%","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2602955406","title":"ArriVent Buy Rating: Favorable Risk‑Reward on Firmonertinib Ahead of Pivotal FURVENT Phase 3 Readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2602955406","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602955406?lang=en_us&edition=fundamental","pubTime":"2026-01-12 00:46","pubTimestamp":1768149985,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma, Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam Slutsky from LifeSci Capital mai...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/arrivent-buy-rating-favorable-risk‑reward-on-firmonertinib-ahead-of-pivotal-furvent-phase-3-readout-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/arrivent-buy-rating-favorable-risk‑reward-on-firmonertinib-ahead-of-pivotal-furvent-phase-3-readout-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4585","XBI","BK4588","BK4581","LABU","BK4139","AVBP"],"gpt_icon":0},{"id":"2593749490","title":"ArriVent BioPharma Initiated at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2593749490","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593749490?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:06","pubTimestamp":1766495160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 23, 2025 08:06 ET (13:06 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP"],"gpt_icon":0},{"id":"2593480424","title":"BRIEF-Arrivent Announces First Patient Dosed In Global Pivotal Phase 3 Alpacca Trial Evaluating Firmonertinib For First-Line Treatment Of EGFR PACC Mutant Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2593480424","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593480424?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:20","pubTimestamp":1766409631,"startTime":"0","endTime":"0","summary":"BRIEF-Arrivent Announces First Patient Dosed In Global Pivotal Phase 3 Alpacca Trial Evaluating Firmonertinib For First-Line Treatment Of EGFR PACC Mutant Non-Small Cell Lung CancerDec 22  - Arrivent Biopharma Inc AVBP.O:ARRIVENT ANNOUNCES FIRST PATIENT DOSED IN GLOBAL PIVOTAL PHASE 3 ALPACCA TRIAL EVALUATING FIRMONERTINIB FOR FIRST-LINE TREATMENT OF EGFR PACC MUTANT NON-SMALL CELL LUNG CANCERSource text: ID:nGNXJ44pFurther company coverage: AVBP.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUA44RLTH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2593487081","title":"Arrivent Announces First Patient Dosed in Global Pivotal Phase 3 Alpacca Trial Evaluating Firmonertinib for First-Line Treatment of Egfr Pacc Mutant Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2593487081","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593487081?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:00","pubTimestamp":1766408402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUA44RLTH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVBP","BK4139"],"gpt_icon":0},{"id":"2590368582","title":"ArriVent BioPharma Initiated at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2590368582","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590368582?lang=en_us&edition=fundamental","pubTime":"2025-12-10 20:43","pubTimestamp":1765370580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 10, 2025 07:43 ET (12:43 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVBP","BK4139"],"gpt_icon":0},{"id":"2590823835","title":"BTIG Initiates ArriVent BioPharma at Buy With $45 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2590823835","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590823835?lang=en_us&edition=fundamental","pubTime":"2025-12-10 20:40","pubTimestamp":1765370459,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma (AVBP) has an average rating of buy and mean price target of $40.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVBP"],"gpt_icon":0},{"id":"2590584948","title":"Arrivent Biopharma Inc : Btig Initiates Coverage With Buy Rating; Price Target $45","url":"https://stock-news.laohu8.com/highlight/detail?id=2590584948","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590584948?lang=en_us&edition=fundamental","pubTime":"2025-12-10 20:24","pubTimestamp":1765369464,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nFWN3XG0LZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVBP","BK4139"],"gpt_icon":0},{"id":"2590054413","title":"U.S. RESEARCH ROUNDUP-JP Morgan, Pepsico, Pfizer","url":"https://stock-news.laohu8.com/highlight/detail?id=2590054413","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590054413?lang=en_us&edition=fundamental","pubTime":"2025-12-10 14:43","pubTimestamp":1765349009,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-JP Morgan, Pepsico, Pfizer Dec 10 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including JP Morgan, Pepsi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nL4N3XG0E5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVS","BTI","CARR","BMY","LU0096364046.USD","CAPR","T","CAT","APD","IE00B19Z9Z06.USD","BIIB","LU0321505868.SGD","LU2746668974.SGD","LU0942090050.USD","BLLN","BWB","AVBP","SG9999011175.SGD","CMC","LU1868837136.USD","PLAY","ASMB","AZO","DBI","AVAV","BRZE","BDX","IE00B3PB1722.GBP","COF","APGE","CHD","ASO","ABBV","DE","LU1868836914.USD","LU2133065610.SGD","AMGN","CPB","ELAN","CNM","ANDE","CMCSA","CF","IE00BDGV0183.EUR","SATS","AU","ANF","CBRL","IE00B894F039.SGD","AMRZ"],"gpt_icon":1},{"id":"2586408769","title":"ArriVent BioPharma Initiated at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2586408769","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586408769?lang=en_us&edition=fundamental","pubTime":"2025-11-26 02:12","pubTimestamp":1764094320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 25, 2025 13:12 ET (18:12 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2586841422","title":"Arrivent Biopharma Inc : Truist Securities Initiates Coverage With Buy Rating; Target Price $43","url":"https://stock-news.laohu8.com/highlight/detail?id=2586841422","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586841422?lang=en_us&edition=fundamental","pubTime":"2025-11-25 19:11","pubTimestamp":1764069080,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nFWN3X109O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2586422890","title":"Truist Initiates ArriVent BioPharma at Buy With $43 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2586422890","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586422890?lang=en_us&edition=fundamental","pubTime":"2025-11-25 19:10","pubTimestamp":1764069017,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma (AVBP) has an average rating of buy and mean price target of $40.10, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVBP"],"gpt_icon":0},{"id":"1189240324","title":"Stock Track | ArriVent BioPharma Soars 5.21% Ahead of Anticipated Q4 Earnings Report","url":"https://stock-news.laohu8.com/highlight/detail?id=1189240324","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189240324?lang=en_us&edition=fundamental","pubTime":"2025-11-13 04:38","pubTimestamp":1762979901,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma (AVBP) saw its stock price surge 5.21% during Wednesday's intraday trading session, as investors position themselves ahead of the company's upcoming fourth-quarter earnings report....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AVBP"],"gpt_icon":0},{"id":"1154323013","title":"Stock Track | ArriVent BioPharma Soars 5.21% Ahead of Q4 Earnings Report","url":"https://stock-news.laohu8.com/highlight/detail?id=1154323013","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154323013?lang=en_us&edition=fundamental","pubTime":"2025-11-13 04:38","pubTimestamp":1762979899,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma (AVBP) saw its stock price surge 5.21% during Wednesday's trading session, as investors show optimism ahead of the company's upcoming fourth-quarter earnings report. The...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AVBP"],"gpt_icon":0},{"id":"2582327400","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2582327400","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582327400?lang=en_us&edition=fundamental","pubTime":"2025-11-12 19:00","pubTimestamp":1762945200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·CI&T Inc. Class A                               3Q       .10        AMC. ·Digi Intl Inc.                                  4Q       .51    4:00 PM","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AIRG","AEBI","AKRO","AMAT","MGX","BABA","ALH","CSCO","CURI","ALMS","AUTL","CRMD","LUNG","AEMD","ARDT","AFYA","ARCO","CPRT","ATAT","CRMT","ATXS","ALUR","ALC","AFCG","CLBT","CINT","ABSI","BLDP","CREX","IBTA","IMRX","RSKD","ABEO","ARX","CELC","ABOS","ALVO","CCAP","AYTU","TWFG","BEEM","ACXP","GUTS","ASND","ANNX","AVBP","PYPD","CABA","CAAP"],"gpt_icon":1},{"id":"2582390854","title":"ArriVent BioPharma, Inc.: Strategic Advancements and Promising Developments Drive Buy Rating with $45 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2582390854","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582390854?lang=en_us&edition=fundamental","pubTime":"2025-11-12 05:15","pubTimestamp":1762895740,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Soumit Roy has maintained their bullish stance on AVBP stock, giving a Buy rating today. Soumit Roy has given his Buy rating d...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/arrivent-biopharma-inc-strategic-advancements-and-promising-developments-drive-buy-rating-with-45-price-target-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/arrivent-biopharma-inc-strategic-advancements-and-promising-developments-drive-buy-rating-with-45-price-target-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVBP"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":54,"code":"91000000","status":"200"}]}}